Background and aims: The emergence of infections due to multi resistant Gram negative bacteria is a major public-
Introduction
Polymyxins (colistin and polymyxin B) are one of the last available options for the treatment of multi-resistant Gram negative bacterial infections. However, mortality rates ranging from 47 to 67.6% have been reported in patients treated with polymyxins in monotherapy. (Elias,2010; Kvitko,2011; Tuon,2014; Rigatto,2015) Besides these high mortality rates, growing incidence of resistance to polymyxins is a current public health concern worldwide. In infections due to Klebsiella pneumoniae, resistance rates to polymyxins in up to 43% of the isolates have been reported. (Monaco, 2014) Pan-resistant bacteria have been isolated with growing frequency, imposing an important therapeutic challenge. (Bialvaei, 2015) Combination treatment may lead to synergism between antibiotics enhancing its bactericidal effect and reducing the Review Nov-Dec, 2015; 1(4): 91-96 ppcr.org/journal/home-current ISSN: 2378 ISSN: -1890 emergence of resistant strains. (Zusman, 2013) Another possible benefit of this strategy is to allow the use lower dose of each antibiotic, reducing adverse effects. In vitro and clinical studies have evaluated the benefit of combining polymyxins with many other antibiotic classes with conflicting results. This review aims to summarize the main studies assessing the potential benefit of combination therapy.
Methods Literature search
This manuscript is an updated version adapted from a PhD thesis published at http://hdl.handle.net/10183/119424. We searched on PUBMED database-for the mesh terms: "polymyxins", "polymyxin B", "colistin", "combination therapy" and their combinations. Articles published in the last 10 years (2005) (2006) (2007) (2008) (2009) (2010) (2011) (2012) (2013) (2014) (2015) -in English language-were selected for analysis if they evaluated combination therapy of other antimicrobial classes with polymyxins. In clinical studies, only the ones that evaluated intravenous use of polymyxins were reviewed. The searched publications were not limited by number of citations or impact factor. The revised manuscripts were divided according to Figure 1 .
Definitions
Bactericidal effect and classification of combination as synergic, antagonistic and indifferent, in the in vitro studies, was defined through two main methods: time-kill and Checkerboard. In time-kill studies, synergism is defined as 2-log reduction in bacterial colony forming units (CFU) when exposed to combination therapy compared to the bacterial activity of the most active antimicrobial alone. Bactericidal activity is defined as 3-log reduction in CFU when exposed to combined therapy compared to the most active agent alone. Antagonism is defined as 2-log increase in CFU after exposure to combination therapy. Bactericidal effect is evaluated after 24 hours of antibiotic exposure. (Zusman, 2013) In Checkerboard method the minimal inhibitory concentrations (MIC) of each drug combined is added and divided by the MIC of each drug alone. An index ≤0,5 is considered synergism, >0,5 and ≤1 additive, >1 indifferent e > 4 antagonistic. (Zusman, 2013) 
Results and Discussion
In vitro studies
The most studied combination is of polymyxins with beta-lactams, mostly carbapenems. A meta-analysis of 59 studies showed benefit of combination in every bacteria species studied (Acinetobacter baumannii, Pseudomonas aeruginosa and Klebsiella pneumoniae). The greater effect was shown in A. baumannii species in which synergy occurred in 77% (95%Confidence Interval [CI] 64-87%) of the samples tested, with an increase in bactericidal rate of 26% (95%CI 12-47%) to 74% (95%CI 58-85%) with combination therapy. (Zusman, 2013) Most studies evaluated colistin, but the few ones that evaluated polymyxin B retrieved fairly similar results. Synergistic effect remained in polymyxin susceptible and carbapenem resistant strains, with rates ranging from 55-71%. Among carbapenems, doripenem had the higher synergistic effect overall, followed by meropenem and imipenem. As an exception, in P. aeruginosa strains, imipenem showed greater activity than meropenem. When isolates were resistant to both polymyxins and carbapenems, combination therapy resulted in an increase of bactericidal activity from 14% (95%CI 7-27%) to 43% (95%CI 21-68%). Sinergy was evaluated through chekerboard method in 23 studies. A synergy index < 1 was found in 71% and 29% of A. baumannii and P.aeruginosa strains, respectively. (Zusman, 2013) Hollow-fiber infection models over 10 days simulated colistin and doripenem treatments against two heteroresistant and one resistant P. aeruginosa strains. Combinations in various regimens showed greater bactericidal effect in up to 9.38 log 10 compared to monotherapy. In the resistant strain, combination led to 6.11 log 10 CFU/mL greater bactericidal effect, but regrowth was observed after 72 hours. (Ly, 2015) Besides increasing bactericidal rates, reducing resistance development during polymyxin therapy was another advantage of combining antibiotics. (Zusman, 2013; Ly, 2015) In biofilms caused by P.aeruginosa, the combination of colistin and doripenem resulted in suppression of resistant strains and synergistic effect that remained for more than 72 hours. (Lora-Tamayo, 2014) Combining polymyxins with beta-lactams other than carbapenems resulted in much lower synergistic rates: cefoperazone/sulbactam (2 of 50 samples), piperacilin/tazobactan (1 of 50 samples). (Karaoglan, 2013) Decrease in the initial MIC was seen for polymyxins and/or beta-lactam when they were combined in up to 35.29% of associations with ceftazidime, 41% with cefepime and 35.29% with piperacilin. Although MIC decrease was seen with the 3 beta-lactams evaluated, in none of the combinations an index ≤0.5 was achieved. (Mitsugui, 2011) Besides beta-lactams, other antibiotic classes have been studied in combination with polymyxins. The main findings are summarized in Table 1. In vitro studies show, in general, very promising results regarding combination therapy with polymyxins in many aspects: higher bactericidal rates, MIC reductionseventually allowing antibiotic dose reductions to less toxic levels, suppression of resistant strains and regrowth inhibition. More consistent evidence is found with carbapenem combinations, but favorable results were also achieved combining polymyxins with other antibiotic classes. Time-kill and checkerboard are the most used methods to evaluate synergy in in vitro models, however they do not account for different drug infusion regimens and total body distribution, which might greatly affect bactericidal capacity. Hollo-fiber models can better simulate these different scenarios and have also shown positive results with combination therapy. However, replicating these findings in a clinical setting is a major challenge considering the complexity of biological systems and the role of immunity, bacteria inoculum and antibiotic distribution and concentrations in different infection sites. Clinical studies are therefore fundamental to evaluate the benefit of these strategies.
Clinical studies
In a case series of 18 patients with infections caused by Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumoniae, the ones who received combined therapy with polymyxin B (mostly tygycicline) had better survival than the ones treated with monotherapy, 73% versus 14%, respectively (Hisch, 2010) . In a study that evaluated 35 patients with K. pneumoniae bacteremia treated with in vitro suceptible antibiotics, there were no deaths in the group of 9 patients treated with colistin and tygecycline, while 7 of 15 (46.7%) died in the monotherapy group (P=0.001). In the later, mortality rates were similar to the group of patients who received in vitro non-susceptible therapy and emergence of resistant strains were identified. (Zarkotou, 2011) Another study with 41 patients with bacteremia by KPC-producer K. pneumoniae showed that in the 28-day survival group 13 of 25 (52%) patients had received combined therapy compared to 2 of 10 (12.5%) in the non-survival group (P=0.001 ventilator associated pneumonia due to XDR-A.baumannii that were treated either with colistin in monotherapy or combined with rifampicin 600mg/day. In the monotherapy group 14 of 22 (63.6%) patients died compared to 8 of 21 38.1%) patients in the combined therapy group (P=0.171). Microbiological eradication was higher in patients that received combined therapy (P=0.029). (Aydemir,2013) Another randomized clinical trial evaluated the same combination including a larger sample in order to increase the study power. Two hundred and ten critically ill patients were analyzed and no statistically significant difference was found in mortality between colistin in monotherapy group versus rifampicin combined therapy group (P=0.97). As shown in the previous study, microbiological eradication was higher in the combined therapy group (P=0.034). (Durante-Mangoni, 2013) Other combinations were also evaluated in the treatment of A.baumannii infections. A restrospective multicenter study included 36 patients that received colistin in monotherapy and 214 that were treated with combination therapy-most frequently with carbapenems (47.7%). Fourteen-day mortality was comparable between groups in univariate and multivariate analyzes and also after adjustment for a propensity score. The combined therapy group had higher microbiological eradication and lower inhospital mortality in univariate analysis (52.3% versus 72.2%; P=0.03). There was no significant difference in mortality between the combinations: colistin and carbapenem, colistin and sulbactan, colistin and other. (Batirel,2014) Another study including 101 patients with A.baumannii sepsis, in which 68 (67.3%) received monotherapy (with colistin or carbapenem) and 33 (32.7%) combined therapy (most frequently colistin and tygecyclin) also showed no difference in 30-day mortality between groups. In this study patients were classified as receiving combined therapy only when there was in vitro susceptibility to both agents or MIC<32 mg/L for carbapenems -all other patients were considered as receiving monotherapy.(Lopez-Cortes, 2014) A recent cohort was the first to show benefit of combination therapy in non-fermentative Gram negative bacteria. One-hundred and one critically ill patients with infections due to XDR-A.baumannii or P.aeruginosa treated either with polymyxin B alone or combined to an in vitro resistant antibiotic. Thirty-day mortality was 59.4% (60 patients): 42.4% (14 of 33) in combination and 67.6% (46 of 68) in monotherapy groups (P=0.03). The mortality protection of combination therapy remained significant in and lower respiratory tract infections also showed benefit of combination therapy. (Rigatto, 2015) Another observational study compared the most effective combination regimen in 55 patients with A. baumannii bacteremia: colistin-tigecycline or colistin-carbapenem. Fourteen-day mortality was higher in patients in colistintigecycline group 35% versus 15% (P=0.105). In the subgroup of patients with tigecycline MIC>2 mg/L, the combination with this drug was independently associated with higher 14-day mortality (HR 6.93; 95%CI 1.61-29.78, P=0.009).
Breakthrough of XDR-A. baumannii bacteremia occurred in 18% of patients that received combination with tigecycline and in none of the carbapenem group (P=0.059). (Cheng, 2015) The combination of glicopetides and colistin was evaluated in 2 retrospective studies. (Garnacho-Montero, 2013; Petrosillo,2014) In only one of these studies an independent protective effect of combination was found in patients that survived for ≥5 days after the beginning of treatment. ( Petrosillo,2014) Clinical studies assessing combination therapy were observational in all but 2 studies, with prescription bias, imbalance of confounding variables between groups and variability of primary outcomes being important limitations for definitive conclusions. Heterogeneity in the definition of combination therapy is also a major issue when comparing these results. Different drug combinations, lack to report time to begin combination and/or duration of combined regimens affects data interpretation. The combination with in vitro susceptible agents also should be cautiously analyzed, once the benefit may arise of adding a more active drug in the therapeutic scheme rather than of synergy between drugs. Nevertheless, clinical data reviewed in this article systematically points toward benefit of combination especially in KPC-K .pneumoniae infections, with recent studies also suggesting this benefit in nonfermentative Gram-negative bacteria.
Conclusion
In times of increasing pan-drug resistance and few therapeutic options to treat severe infections by XDR-Gram negative bacteria, polymyxin combination regimens seems as potentially advantageous in the treatment of these patients. However, data evaluating its benefit are not yet conclusive. Randomized clinical trials assessing different antibiotic combinations in infections by enterobacteriaceae and non-fermentative Gram negative bacteria are urgently needed.
